Results show combined therapy improves outcomes in women with advanced breast cancer, suggesting a new treatment option.
In these pretreated participants, camizestrant 75 mg in combination with capivasertib 400 mg was well tolerated, with a side effect profile consistent with each drug as monotherapy, and showed encouraging evidence of clinical efficacy.
No takes yet. Share an insight, caveat, or question.
Vaklavas et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: